Last reviewed · How we verify
PCV13i
PCV13i is a conjugate vaccine that stimulates the body's immune response to protect against invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F.
PCV13i is a conjugate vaccine that stimulates the body's immune response to protect against invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F. Used for Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F.
At a glance
| Generic name | PCV13i |
|---|---|
| Sponsor | CanSino Biologics Inc. |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
PCV13i works by introducing inactivated fragments of the pneumococcal capsular polysaccharides to the body, which triggers the production of antibodies that can recognize and neutralize the corresponding serotypes of S. pneumoniae. This immune response helps to prevent invasive pneumococcal disease, including pneumonia, meningitis, and sepsis.
Approved indications
- Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
Key clinical trials
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (PHASE3)
- Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) (PHASE3)
- Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PCV13i CI brief — competitive landscape report
- PCV13i updates RSS · CI watch RSS
- CanSino Biologics Inc. portfolio CI